ClinicalTrials.gg
Active, not recruitingNCT02436993Updated Nov 12, 2026Results posted

Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab

A Phase 2 interventional study of Carboplatin and Paclitaxel in Breast Carcinoma, sponsored by University of California, Irvine. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University of California, Irvine · Phase 2, Interventional, and Treatment

How we know · 14 judgments · 4 readings being read again

Updated Nov 12, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 131 studies testing bevacizumab in Breast Neoplasms — 9 open to participants now, 10 under way, none of them phase 3. Bevacizumab · Breast Neoplasms.

Enrollment
36th of 130
120 · median 58
Started
2015
the only one that year
Phase 2
89 of 131
6 open now
Registered
116th of 131
by date
Lead sponsor
3 of 131
University of California, Irvine

Among the 131 studies testing bevacizumab in Breast Neoplasms, this one is the 36th largest by enrollment of the 130 interventional ones that give a count, is the only one that started in 2015, is one of 89 in phase 2, and was the 116th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 131 studies testing bevacizumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies testing bevacizumab in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this phase II is to study the efficacy and toxicity of carboplatin and paclitaxel with pertuzumab and trastuzumab in HER2 positive and carboplatin and paclitaxel with bevacizumab in HER2 negative in the neoadjuvant setting for the treatment of breast cancer.

Read the detailed description

OBJECTIVES The study component is to evaluate the treatment response and toxicity of the protocol.

Objectives for treatment study component:

1.1 To estimate 2-year progression-free survival in patients with breast cancer with tumor more than 1 cm and/or with clinically detected lymph node treated with neoadjuvant weekly Carboplatin and Paclitaxel combined with Trastuzumab + Pertuzumab in HER2-positive disease or with Bevacizumab in HER2-negative disease.

1.2 To measure the microscopic complete pathological response (pCR) rates defined as ypT0 or ypTis tumors in patients treated with this regimen in the neoadjuvant setting.

1.3 To assess complete clinical response (cCR) rates after treatment by physical exam and imaging tests (ultrasonography, mammography, or magnetic resonance imaging) clinical objective response rate (by Response Evaluation Criteria In Solid Tumors (RECIST)) 1.4 To determine the toxicity of this regimen. 1.5 To determine treatment adherence and delivered dose intensity of this regimen.

1.6 To assess the correlation between pCR and cCR. 1.7 To determine the rate of breast conservation following neoadjuvant therapy. 1.8 Determine treatment efficacy according to subgroups defined according to stage and receptor status.

03

Conditions studied

  • Breast Carcinoma

Browse trials for

Keywords

  • Neoadjuvant Treatment
  • Carboplatin
  • Paclitaxel
  • Pertuzumab
  • Trastuzumab
  • Bevacizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. proven unilateral or bilateral primary breast carcinoma. (In case of bilateral cancer, the investigator has to decide prospectively which side will be evaluated for the primary endpoint.)
  2. Tumor size is clinically at least 1 cm in greatest diameter (palpable or by imaging) and/or with involved lymph node. In case of inflammatory disease, the extent of inflammation may be the .
  3. Documentation of inflammatory breast cancer
  4. Woman age > or = 18
  5. Performance status of 0-2 by (ECOG) criteria
  6. Known status
  7. Normal cardiac function must be documented within 90 days prior to registration either via an ECHO or or per physician's review of symptoms and medical history. If an ECHO is performed as standard of care, the ejection fraction must be above the normal limit of the institution.. If not available in the medical chart, the ECHOs or MUGAs are not required to be repeated for research purposes.

    a. Date of Echo or multigated acquisition (MUGA) (within 90 days) if performed

  8. Staging work-up prior to registration

    1. Date of physical examination (within 90 days)
    2. Date of bilateral mammogram (within 90 days)
    3. Date of breast ultrasound (within 90 days)
    4. Date of MRI breast (within 30 days)
    5. Chest X-ray or CT- Chest or CT/PET Scan that includes the Chest may be done at physician's discretion (within 90 days). If not available in the medical chart, the Chest X-ray or CT- Chest or CT/PET Scan that includes the Chest is not required to be repeated for research purposes.
    6. Other tests as clinically indicated
  9. Laboratory requirements:

    1. Hematology:

      • (ANC) ≥ 1,500/μl
      • ≥ 100,000/μl
    2. Hepatic Function

      • Total \<1x (ULN)
      • (AST) and alanine aminotransferase (ALT) ≤ 2x ULN
    3. Renal Function

      - Creatinine \<1.5x ULN

    4. Proteinuria

      - Random urine total protein \<100mg/dL. Urine Protein Creatinine (UPC) ratio \<2g

    5. Negative pregnancy test for women of within 14 days prior to registration.
  10. All patients must be informed of the nature of this study and must sign and give written in accordance with institutional and federal guidelines.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of distant . If radiographic suspicion of distant metastatic site, a negative must be available in the medical record. If not available in the medical record, the subject may be included and a confirmatory biopsy is not required to be performed for research purposes.
  2. Known or suspected congestive heart failure, angina pectoris requiring antianginal medication, or other cardiac condition.
  3. Pregnant or nursing women may not participate due to the possibility of harm to fetus or nursing infants from this treatment regimen. Women of may not participate unless they have agreed to use an adequate method throughout study treatment and for one month after completion of treatment.
  4. Male patients
  5. Pre-existing peripheral neuropathy of severity grade ≥ 2 (limiting instrumental activities of daily living).
  6. Incomplete wound healing.
  7. Active and significant bleeding
  8. Known allergy, or prior infusion reaction to one or more of the therapies incorporated into this treatment protocol.
  9. Bone marrow depression or hematologic parameters in the range that would increase the risk for severe bleeding.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Carboplatin+Paclitaxel+Bevacizumab (HER2-)

    Carboplatin weekly 12 doses Paclitaxel weekly 12 doses Bevacizumab every other week, 5 doses

    Drug: Carboplatin · Drug: Paclitaxel · Drug: Bevacizumab

  • Experimental
    Carboplatin+Paclitaxel+Trastuzumab+Pertuzumab (HER2+)

    Carboplatin weekly 12 doses Paclitaxel weekly 12 doses Trastuzumab weekly 12 doses Pertuzumab every 3 weeks, 4 doses

    Drug: Carboplatin · Drug: Paclitaxel · Drug: Trastuzumab · Drug: Pertuzumab

Interventions

  • Area Under the Curve (AUC) 2 IV over 60 minutes weekly for 12 doses

    Also known as: Paraplatin

  • 80 mg/m\^2 IV over 1-3 hours weekly for 12 doses

    Also known as: Taxol

  • 10mg/kg IV over 90 or 60 or 30 minutes every other week for 5 doses

    Also known as: Avastin

  • 4mg/kg induction, followed by weekly 2mg/kg IV-induction over 90 minutes, then weekly over 30-60 minutes for 12 doses

    Also known as: Herceptin

  • 840mg induction, followed by 420mg every 3 weeks IV-induction over 60 minutes, then every 3 weeks over 30-60 minutes for 4 doses

    Also known as: Perjeta

06

What researchers measure

Primary outcomes

  1. 2-year Progression Free Survival in Patients Treated With Weekly Carboplatin and Paclitaxel Combined With Either Trastuzumab and Pertuzumab for HER2-positive Patients or Bevacizumab for HER2-negative Patients in the Neoadjuvant Setting

    Progression of disease-A new lesion or a greater than or equal to 25% increase in the product of the largest perpendicular diameters of any one lesion on clinical exam or by U/S or MRI Survival-from date of registration to date of death

    Time frame: 2 years

Secondary outcomes

  1. Clinical Complete Response Rates

    Clinical complete response (cCR)-Normal breast on physical exam. No mass, no thickening, no erythema, no peau d'orange

    Time frame: 2 years

  2. Pathologic Complete Response Rates

    Pathologic complete response (pCR)-No histologic evidence of microscopic invasive tumor at the primary tumor site in the surgical specimen (ypT0 or DCis)

    Time frame: 2 years

  3. Number of Toxicities in Carboplatin+Paclitaxel+Bevacizumab (HER2) Arm

    This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 for toxicity and Adverse Event reporting.

    Time frame: Up to 42 days after discontinued treatment

  4. Number of Toxicities in Carboplatin+Paclitaxel+Trastuzumab+Pertuzumab (HER2+)

    This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 for toxicity and Adverse Event reporting.

    Time frame: Up to 42 days after discontinued treatment

07

Results

Posted Nov 12, 2026

Participant flow

Participant flow — Overall Study
MilestoneCarboplatin + Paclitaxel+ Bevacizumab (HER2-)Carboplatin + Paclitaxel + Trastuzumab+ Pertuzumab (HER2+)
Started7248
Completed7248
Not completed00

Outcome measures

Primary2-year Progression Free Survival in Patients Treated With Weekly Carboplatin and Paclitaxel Combined With Either Trastuzumab and Pertuzumab for HER2-positive Patients or Bevacizumab for HER2-negative Patients in the Neoadjuvant Setting

Progression of disease-A new lesion or a greater than or equal to 25% increase in the product of the largest perpendicular diameters of any one lesion on clinical exam or by U/S or MRI Survival-from date of registration to date of death

Time frame:
2 years
Reported as:
Number · Percentage
2-year Progression Free Survival in Patients Treated With Weekly Carboplatin and Paclitaxel Combined With Either Trastuzumab and Pertuzumab for HER2-positive Patients or Bevacizumab for HER2-negative Patients in the Neoadjuvant Setting
PercentageArm 1: Her2-negative (HER2-)Arm 2: Her2-positive (HER2+)
2-year Progression Free Survival in Patients Treated With Weekly Carboplatin and Paclitaxel Combined With Either Trastuzumab and Pertuzumab for HER2-positive Patients or Bevacizumab for HER2-negative Patients in the Neoadjuvant Setting68.2 (51.7 to 84.7)90.3 (81.1 to 99.5)
SecondaryClinical Complete Response Rates

Clinical complete response (cCR)-Normal breast on physical exam. No mass, no thickening, no erythema, no peau d'orange

Time frame:
2 years

Results for this outcome have not been posted.

SecondaryPathologic Complete Response Rates

Pathologic complete response (pCR)-No histologic evidence of microscopic invasive tumor at the primary tumor site in the surgical specimen (ypT0 or DCis)

Time frame:
2 years

Results for this outcome have not been posted.

SecondaryNumber of Toxicities in Carboplatin+Paclitaxel+Bevacizumab (HER2) Arm

This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 for toxicity and Adverse Event reporting.

Time frame:
Up to 42 days after discontinued treatment

Results for this outcome have not been posted.

SecondaryNumber of Toxicities in Carboplatin+Paclitaxel+Trastuzumab+Pertuzumab (HER2+)

This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 for toxicity and Adverse Event reporting.

Time frame:
Up to 42 days after discontinued treatment

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events and serious adverse events will begin to be collected when the participant starts treatment until 30 days after the end of treatment. Approximately 6 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 111/72 (15.3%)11/72 (15.3%)68/72 (94.4%)
Arm 24/48 (8.3%)4/48 (8.3%)40/48 (83.3%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventArm 1Arm 2
DiarrheaGastrointestinal disorders2/721/48
Skin infectionInfections and infestations2/720/48
Febrile neutropeniaBlood and lymphatic system disorders1/721/48
ConstipationGastrointestinal disorders0/721/48
AppendicitisInfections and infestations0/721/48
Gastric perforationGastrointestinal disorders1/720/48
DiverticulitisGastrointestinal disorders1/720/48
Oral hemorrhageGastrointestinal disorders1/720/48
Rectal BleedingGastrointestinal disorders1/720/48
Nose BleedGeneral disorders1/720/48
Most frequent other events
Showing 10 of 46
Most frequent other events
EventArm 1Arm 2
DiarrheaGastrointestinal disorders25/7234/48
FatigueGeneral disorders41/7219/48
NauseaGastrointestinal disorders37/7224/48
EpixstasisReproductive system and breast disorders37/729/48
ConstipationGastrointestinal disorders35/725/48
Neutrophil Count IncreasedInvestigations34/7220/48
AlopeciaSkin and subcutaneous tissue disorders33/7210/48
Peripheral Sensory NeuropathyNervous system disorders31/7218/48
InsomniaPsychiatric disorders25/725/48
HeadacheNervous system disorders23/7211/48

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Carboplatin + Paclitaxel+ Bevacizumab (HER2-)Carboplatin + Paclitaxel + Trastuzumab + Pertuzumab (HER2+)Total
Median52 (28 to 76)53.5 (26 to 81)53 (26 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)Carboplatin + Paclitaxel+ Bevacizumab (HER2-)Carboplatin + Paclitaxel + Trastuzumab + Pertuzumab (HER2+)Total
Female7248120
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Carboplatin + Paclitaxel+ Bevacizumab (HER2-)Carboplatin + Paclitaxel + Trastuzumab + Pertuzumab (HER2+)Total
Hispanic or Latino331750
Not Hispanic or Latino383068
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Carboplatin + Paclitaxel+ Bevacizumab (HER2-)Carboplatin + Paclitaxel + Trastuzumab + Pertuzumab (HER2+)Total
American Indian or Alaska Native101
Asian171128
Native Hawaiian or Other Pacific Islander112
Black or African American112
White373067
More than one race303
Unknown or Not Reported12517
Region of Enrollment
Region of Enrollment(participants)Carboplatin + Paclitaxel+ Bevacizumab (HER2-)Carboplatin + Paclitaxel + Trastuzumab + Pertuzumab (HER2+)Total
United States7248120
08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Nov 2023 and a completion of Dec 2036. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2026, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2015
First posted
May 7, 2015
Start
Apr 2015
Primary completionActual
Nov 2023
CompletionEst.
Dec 2036
Results first posted
Nov 12, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 12, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • Edited2-year progression free survivalProgression Free Survival in patients treated with weekly carboplatinPatients Treated With Weekly Carboplatin and paclitaxel combined with either trastuzumabPaclitaxel Combined With Either Trastuzumab and pertuzumabPertuzumab for HER2-positive patientsPatients or bevacizumabBevacizumab for HER2-negative patientsPatients in the neoadjuvant settingNeoadjuvant SettingTime frame: 2 years
Nov 12, 2026
Documents
Secondary outcomes
4 edited
What changed in the outcomes
  • EditedClinical complete response ratesComplete Response RatesTime frame: 2 years
  • EditedPathologic complete response ratesComplete Response RatesTime frame: 2 years
  • EditedNumber of toxicitiesToxicities in Carboplatin+Paclitaxel+Bevacizumab (HER2) armArmTime frame: Up to 42 days after discontinued treatment
  • EditedNumber of toxicitiesToxicities in Carboplatin+Paclitaxel+Trastuzumab+Pertuzumab (HER2+)Time frame: Up to 42 days after discontinued treatment
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • Edited2-year progression free survivalProgression Free Survival in patients treated with weekly carboplatinPatients Treated With Weekly Carboplatin and paclitaxel combined with either trastuzumabPaclitaxel Combined With Either Trastuzumab and pertuzumabPertuzumab for HER2-positive patientsPatients or bevacizumabBevacizumab for HER2-negative patientsPatients in the neoadjuvant settingNeoadjuvant SettingTime frame: 2 years
    Secondary outcomes 4 edited
    What changed in the outcomes
    • EditedClinical complete response ratesComplete Response RatesTime frame: 2 years
    • EditedPathologic complete response ratesComplete Response RatesTime frame: 2 years
    • EditedNumber of toxicitiesToxicities in Carboplatin+Paclitaxel+Bevacizumab (HER2) armArmTime frame: Up to 42 days after discontinued treatment
    • EditedNumber of toxicitiesToxicities in Carboplatin+Paclitaxel+Trastuzumab+Pertuzumab (HER2+)Time frame: Up to 42 days after discontinued treatment
    + 5 other changes: index terms, verification date, responsible party, contact details and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02436993
Responsible party
Ritesh Parajuli (Associate Clinical Professor, University of California, Irvine) — Principal investigator
First posted
May 7, 2015
Start date
Apr 2015
Primary completion
Nov 2023
Completion
Dec 2036 (estimated)
Results posted
Nov 12, 2026
Last update
Nov 12, 2026

Study contacts

Ritesh Parajuli, MD
principal investigator · University of California, Irvine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Trastuzumab · Pertuzumab

Start the discussion